The rise of COVID-19, an omicron-based vaccine variant has brought renewed investor interest to vaccine developers. The success of Pfizer’s (PFE) and BioNTech’s (BNTX) COVID-19 vaccines has helped these stocks soar in price over the past few months, and they could continue gaining. So, we think it could be wise to add them to one’s portfolio now. Continue reading. The COVID-19 Omicron strain, which was only discovered a few weeks back, is the predominant strain in the United States. It accounts for approximately 73% of all cases. Biden’s administration took steps to stop its spread. Last month, the White House’s COVID-19 response coordinator, Jeff Zients, said, “We’re working with Pfizer , Moderna (NASDAQ:), and (Johnson & Johnson) to develop contingency plans for modifications to vaccines or boosters if they’re needed.”

The rapid expansion of this new version in many parts of the globe is likely to drive up demand for COVID-19 booster shots and vaccines. BCC Research reports that vaccine markets worldwide will increase at 7.6% annually over the next five year to reach $55.10 billion.

We believe it would be prudent to place your money on high quality COVID-19 vaccination stocks Pfizer Inc. (NYSE) and BioNTech Se (NASDAQ:). These stocks have seen a significant price increase, particularly with the introduction of the Omicron version. These stocks will continue to rise in the future.

Continue reading on StockNews